ADPT earnings call for the period ending June 30, 2020.
News & Analysis: Adaptive Biotechnologies Corporation
Does this unusual biotech stock have what it takes to deliver market-beating gains?
Investors expect the company's technology platform to come in handy as the world corrals the coronavirus pandemic.
Why Adaptive Biotechnologies and Smartsheet will be mega-cap stocks in the future.
ADPT earnings call for the period ending March 31, 2020.
Revenue skyrocketed in the first quarter. But so did Adaptive's spending.
The "ImmuneRace" study will genetically map the T-cells of 1,000 people who have been exposed to SARS-CoV-19.
One company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.
In the midst of a global market meltdown, I'm buying virtual companies that are winning market share.
This biotech is seeking to understand the immune system to develop insights and drug products for the most vexing health problems, including COVID-19.